Tripartite neuroendocrine activation of the human growth hormone (GH) axis in women by continuous 24-hour GH-releasing peptide infusion: Pulsatile, entropic, and nyctohemeral mechanisms

Journal of Clinical Endocrinology and Metabolism

Volumn 84, Issue 6, 1999, Pages 2140-2150

  Shah, N ^a   Evans, W S ^a   Bowers, C Y ^b   Veldhuis, J D ^a,c  

^a NATIONAL SCIENCE FOUNDATION   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR;

ADULT; AGED; ARTICLE; CIRCADIAN RHYTHM; CONTROLLED STUDY; FEMALE; GROWTH HORMONE RELEASE; HUMAN; NEUROENDOCRINE SYSTEM; NORMAL HUMAN; PRIORITY JOURNAL; PULSATILE FLOW;

SUS SCROFA;

EID: 0033304920     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.84.6.2140     Document Type: Article

References (50)

1. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone
2. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone
3. In vitro characterization of four novel classes of growth hormone-releasing peptide
4. Pathophysiology of the neuroregulation of GH secretion in experimental animals and the human
5. The GH, prolactin, ACTH, and cortisol responses to Hexarelin, a synthetic hexapeptide, undergo different age-related variations
6. A receptor in pituitary and hypothalamus that functions in growth hormone release
7. A novel hypothalamic hormone measured in hypophyseal portal plasma drives rapid bursts of GH secretion
8. Growth hormone-releasing hexapeptide elevates intracellular calcium in rat somatotropes by two mechanisms
9. Molecular analysis of rat pituitary and hypothalamic growth hormone secretagogue receptors
10. Growth hormone releasing peptide (GHRP-6) stimulates phosphatidylinositol (PI) turnover in human pituitary somatotroph cells
11. Identification of a pituitary growth hormone-releasing peptide (GHRP) receptor subtype by photoaffinity labeling
12. Central effects of growth hormone-releasing hexapeptide (GHRP-6) on growth hormone release are inhibited by central somatostatin action
13. Somatostatin receptor activation of cellular effector systems
14. Human fetal pituitary expresses functional growth hormone-releasing peptide receptors
15. Atypical growth hormone releasing peptides
16. Central actions of peptide and non-peptide growth hormone secretagogues in the rat
17. Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man
18. Growth hormone (GH)-releasing hormone secretion is stimulated by a new GH-releasing hexapeptide in sheep
19. Intracerebroventicular growth-hormone-releasing peptide-6 stimulates eating without affecting plasma growth hormone responses in rats
20. GH releasing peptides: Structure and kinetics
21. GHRH and GHRP-2 combined stimulate supra-additive GH secretion in men in the presence of low-dose synthetic somatostatin (octreotide): Evidence for a novel interaction between GHRH and GHRP
22. Interaction of the growth hormone releasing peptide hexarelin with somatostatin
23. Absence of growth hormone (GH) secretion after the administration of either GH-releasing hormone (GHRH), GH- releasing peptide (GHRP-6), or GHRH plus GHRP-6 in children with neonatal pituitary stalk transection
24. New modalities for understanding dynamic regulation of the somatotropic (GH) axis: Explication of gender differences in GH neuroregulation in the human
25. Pharmacokinetics and pharmacodynamics of growth hormone-releasing peptide-2: A phase I study in children
26. Low basal and persistent pulsatile growth hormone secretion are revealed in normal and hyposomatotropic men studied with a new ultrasensitive chemiluminescence assay
27. Differential impact of age, sex-steroid hormones, and obesity on basal vs. pulsatile growth hormone secretion in men as assessed in an ultrasensitive chemiluminescence assay
28. The pituitary gland secretes in bursts: Appraising the nature of glandular secretory impulses by simultaneous multiple-parameter deconvolution of plasma hormone concentrations
29. Specific methodological approaches to selected contemporary issues in deconvolution analysis of pulsatile neuroendocrine data
30. An amplitude-specific divergence in the pulsatile mode of GH secretion underlies the gender difference in mean GH concentrations in men and premenopausal women
31. Amplitude modulation of a burst-like mode of cortisol secretion subserves the circadian glucocorticoid rhythm in man
32. Orderliness of hormone release patterns: A complementary measure to conventional pulsatile and circadian analyses
33. Females secrete growth hormone with more process irregularity than males in both human and rat
34. Enhanced basal and disorderly growth hormone secretion distinguish acromegalic from normal pulsatile growth hormone release
35. Estrogen and testosterone, but not a nonaromatizable androgen, direct network integration of the hypothalamo-somatotrope (growth hormone)-insulin-like growth factor I axis in the human: Evidence from pubertal pathophysiology and sex-steroid hormone replacement
36. Endogenous growth hormone secretion and clearance rates in normal boys as determined by deconvolution analysis: Relationship to age, pubertal status and body mass
37. Maturation of the regulation of growth hormone secretion in young males with hypogonadotropic hypogonadism pharmacologically exposed to progressive increments in serum testosterone
38. Somatostatin infusion suppresses GH secretory burst number and mass in normal men: A dual mechanism of inhibition
39. Effect of growth hormone (GH) infusion on GH secretion during rest and exercise
40. Unequal impact of age, percentage body fat, and serum testosterone concentrations on the somatotropic, IGF-I, and IGF-binding protein responses to a three-day intravenous growth hormone-releasing-hormone (GHRH) pulsatile infusion
41. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-0677) in healthy elderly subjects
42. Twenty-four-hour growth hormone (GH)-releasing peptide (GHRP) infusion enhances pulsatile GH secretion and specifically attenuates the response to a subsequent GHRP bolus
43. Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men
44. Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation
45. Inhibition of growth hormone release after the combined administration of GHRH and GHRP-6 in patients with Cushing's syndrome
46. Neuroendocrinology of prolonged critical illness: Effects of exogenous thyrotropin-releasing hormone infusion and its combination with growth hormone-secretagogues
47. The somatotropic axis in critical illness: Effects of continuous GHRH and GHRP-2 infusion
48. Differential orderliness of the GH release process in castrate male and female rats
49. Hexarelin-induced growth hormone, cortisol, and prolactin release: A dose-response study
50. Short-term administration of intranasal or oral Hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging